SparVax: Phase II hold

PharmAthene said FDA placed its SparVax program on clinical hold. According to the company, the agency said PharmAthene will receive a letter providing details of the basis for the hold within 30 days. A Phase II trial of vaccine was slated to begin by year end. ...